Patents Examined by Catherine S Hibbert
  • Patent number: 10377990
    Abstract: The present invention provides mammalian cell lines that have been genetically engineered causing such cell lines to be resistant to viral entry and/or propagation, and provides methods of using said cell lines to reduce or prevent viral contamination of biologic production systems.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: August 13, 2019
    Assignee: SIgma-Aldrich Co. LLC
    Inventors: Nan Lin, Joaquina Mascarenhas, Audrey Chang, David Onions, Henry George, Kevin Kayser
  • Patent number: 10370654
    Abstract: The present disclosure provides compositions and methods for genomic engineering.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 6, 2019
    Assignee: enEvolv, Inc.
    Inventors: Jay H. Konieczka, James E. Spoonamore, Ilan N. Wapinski, Farren J. Isaacs, Gregory B. Foley
  • Patent number: 10351609
    Abstract: Disclosed are methods of determining activity of mTOR variants upon exposure to mTOR inhibitors, such a rapamycin or rapalogs thereof, methods for determining kinase activity of a mTOR variant, and methods for determining tumor cell response to treatment with rapamycin or rapalogs thereof. A method for determining whether a compound inhibits mTOR activity in a cell is also disclosed.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: July 16, 2019
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Elisa A Waxman, Thais Acquafreda
  • Patent number: 10329625
    Abstract: The present invention relates to methods, devices, combinations, kits, and systems for predicting and treating clinically significant prostate cancer in a urine sample of an individual suspected of suffering from prostate cancer based on expression analysis of normalized prostate tumor markers. The present methods, devices, combinations, kits, and systems are especially suitable for predicting and treating prostate cancer with a Gleason score of seven or more in individuals with a serum prostate-specific antigen (sPSA) level lower than 15 ng/ml.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 25, 2019
    Assignee: MDxHealth Research B.V.
    Inventors: Daphne Hessels, Franciscus Petrus Smit, Jack A. Schalken
  • Patent number: 10329587
    Abstract: Methods of modulating expression of a target nucleic acid in a cell are provided including use of multiple orthogonal Cas9 proteins to simultaneously and independently regulate corresponding genes or simultaneously and independently edit corresponding genes.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: June 25, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Kevin M. Esvelt, Prashant G. Mali
  • Patent number: 10329547
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 25, 2019
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Patent number: 10329571
    Abstract: The present invention relates to the dual, independent cistron expression system in a single vector for the production of protein of interest proteins and peptides expressed as insoluble inclusion bodies formed in the bacteria E. coli. The present invention also provides the process for the expression of protein of interest using said bicistronic vector.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: June 25, 2019
    Assignee: Lupin Limited
    Inventors: Shardul Salunkhe, Brajesh Varshney, Sudheerbabu Soorapaneni
  • Patent number: 10323073
    Abstract: Methods and products (e.g., gRNAs, recombinant fusion proteins, frataxin targeting systems, compositions and kits) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering therefrom.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: June 18, 2019
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Jacques P. Tremblay, Pierre Chapdelaine, Joël Rousseau
  • Patent number: 10317329
    Abstract: Provided herein are methods for selecting a population of cells expressing a target polypeptide. In some aspects, the disclosure provides methods for sorting and selecting populations of transfected host cells based on their early expression of a selectable polypeptide. In certain embodiments, the sorting is performed using fluorescence-activated cell sorting or magnetic-activated cell sorting based on the selectable polypeptide. Such selection methods can be further utilized to generate clonal populations of producer cells, e.g. for large-scale manufacturing of a target polypeptide of interest.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 11, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Victor R. Cairns, Christine DeMaria, Jason Vitko
  • Patent number: 10302655
    Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: May 28, 2019
    Assignee: Glaxo Group Limited
    Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka-Swider, Ian Tomlinson
  • Patent number: 10301650
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: May 28, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 10301648
    Abstract: A method of correcting singletons in a selected AAV sequence in order to increasing the packaging yield, transduction efficiency, and/or gene transfer efficiency of the selected AAV is provided. This method involves altering one or more singletons in the parental AAV capsid to conform the singleton to the amino acid in the corresponding position(s) of the aligned functional AAV capsid sequences.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: May 28, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Luk Vandenberghe, Guangping Gao, James M. Wilson
  • Patent number: 10293056
    Abstract: The present invention relates to non-viral gene therapy methods and compositions for treatment of hyperproliferative disease in humans. More specifically, the invention is directed, in one embodiment, to lipid formulations which form stable liposome structures, capable of efficient in vivo nucleic acid transfer. In other embodiments, methods and compositions are directed to liposome transfer of anti-proliferative nucleic acids, wherein the transfer of the nucleic acids is cell specific via cell specific targeting moieties. The present invention, thus provides non-viral, liposome compositions and methods of gene transfer particularly useful for targeting and treating hyperproliferative disease.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: May 21, 2019
    Assignees: Board of Regents, The University of Texas System, Introgen Research Institute, Inc.
    Inventors: Rajagopal Ramesh, Jack A. Roth, Tomoyuki Saeki, Deborah R. Wilson
  • Patent number: 10287593
    Abstract: A filamentous fungus mutant strain in which enzyme production inhibition caused by glucose is suppressed is constructed, and a method of producing a polysaccharide-degrading enzyme, a method of producing a saccharide from biomass, and a method of saccharifying biomass, each using the filamentous fungus, are provided. The filamentous fungus mutant strain in which Sre1 expression is reduced compared to a parent strain or is lost.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: May 14, 2019
    Assignee: Kao Corporation
    Inventors: Toshiharu Arai, Hiroshi Kakeshita
  • Patent number: 10280408
    Abstract: The present invention relates to methods of suppressing the transcriptional expression of one or more genes by methylating the chromatin histone proteins of the one or more genes. Specifically, a viral SET domain histone lysine mehtyltransferase (vSET or vSET-like protein) methylates lysine 27 of a gene's histone protein 3 (H3-K27) thereby suppressing the transcription of the gene.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: May 7, 2019
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Ming-ming Zhou, Shiraz Mujtaba
  • Patent number: 10280419
    Abstract: Methods and products are described related to use of the CRISPR/Cas9 system to introduce a modification into an APP gene, such as guide RNAs and recombinant proteins, for decreasing amyloid beta peptide produced by a cell. Also described are uses of such methods and products for the treatment of Alzheimer's disease and/or age-related cognitive decline in a cell from a subject in need thereof.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: May 7, 2019
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Jacques P. Tremblay, Joël Rousseau, Pierre Chapdelaine
  • Patent number: 10273501
    Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: April 30, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Prashant G. Mali, Luhan Yang
  • Patent number: 10266846
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 23, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 10266899
    Abstract: The present invention provides novel mitochondrial fusion transcripts and the parent mutated mtDNA molecules that are useful for predicting, diagnosing and/or monitoring cancer. Hybridization probes complementary thereto for use in the methods of the invention are also provided.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: April 23, 2019
    Assignee: MDNA Life Sciences Inc.
    Inventors: Ryan Parr, Brian Reguly, Gabriel Dakubo, Jennifer Creed, Kerry Robinson
  • Patent number: 10258697
    Abstract: Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: April 16, 2019
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Zheng-Yi Chen, David Liu, John Anthony Zuris, David B. Thompson